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LETTER TO THE EDITORS
Probabilistic economic model to compare MRCP
with ERCP for the investigation of biliary
obstruction is never complete but an on-going
program
Dear Editor,
In the article by Bravo Vergel et al.1 the authors should
be congratulated for their success in cost containment
and the cost-effectiveness analysis with a final-probabilistic
economic model which was constructed in order to evalu-
ate the relative cost-effectiveness of adopting magnetic
resonance cholangiopancreatography (MRCP) scanning
compared to diagnostic endoscopic retrograde cholangio-
pancreatography (ERCP) for the investigation of biliary
obstruction in adults.
However, the approach is not exactly free of charge, and
requires a lot effort in planning, implementation and
follow-up.
As a matter of fact, a probabilistic economic model
which was constructed in order to evaluate the relative
cost-effectiveness of adopting MRCP scanning compared to
diagnostic ERCP for the investigation of biliary obstruction
in adults is never complete but rather an on-going program.
Therefore, it would be interesting to know that (a) how
much resources were invested in this project; (b) how it
was financed; (c) how the recurring charges will be
handled; and (d) how the improvement of QOL is dependent
of the clinical (not only statistical) pre-procedural base
case values and parameters.
Also, there is concern over the comparability of MRCP and
ERCP patients available from the systematic literature re-
view. All the mentioned study reports are non-randomized
and compared MRCP with either concurrent or historical
ERCP comparison groups. The ERCP patients used as a com-
parison to MRCP patients generally do not present with the
same prevalence of co-morbidity conditions and thus may
not have similar surgical risk profiles. The lack of randomi-
zationand the reporting of non-randomized studiesmayhave
led to a selection bias towards the high surgical risk patients.
MRCP and ERCP are beneficial to relief of symptoms and
improve QOL-level. However, the improvement of QOL is
dependent on the pre-procedural or preoperative QOL and
independent of the preoperative co-morbidities.
The clinical implication is that in patients with good
QOL, even when they have a complaint of jaundice, the
decision to perform MRCP or ERCP must clearly be
discussed and certainly related to the conservative or
operative risk. Certainly in this manuscript MRCP and ERCP
patients in comparison with surgical results would be
interesting.
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Dear Editor,
Your correspondent Dr. Hudorovic´ raised a few points
that require clarification. The article by Bravo Vergel
et al. published in this journal is based on original
research commissioned by the National Coordinating Cen-
tre for Health Technology Assessment (NCCHTA). The
purpose of the NCCHTA HTA programme is to ensure that
high quality research information on the costs, effective-
ness and cost-effectiveness is produced in the most
effective way for those who use, manage and provide
care in the NHS. Every year the NCCHTA and its advisory
panels decide which of the many suggestions received
from the NHS and its users should become research
priorities. The results of the independent research are
Surgical issues in early management of atrial
fibrillation in general surgical in-patients
Dear Editor,
In the article by Walsh et al.1 the authors dealing
with the management of non-cardiac surgical patients
who developed new-onset atrial fibrillation (AF) during
their in-patient stay. They stated that thorough clinical
evaluations are recommended. Minimum evaluation of
the patient with AF includes characterizing the pattern
of the arrhythmia as paroxysmal or persistent, deter-
mining its cause, and defining associated cardiac and
extracardiac factors. Additional investigation may in-
clude Holter monitoring and exercise testing, transeso-
phageal echocardiography, and/or electrophysiological
study.
In patients with persistent AF, there are fundamentally
two ways to manage the dysrhythmia: to restore and
maintain sinus rhythm or to allow AF to continue and
ensure that the ventricular rate is controlled.
In my opinion, it could be interesting to state
something about surgical issues in the management of
patients with AF which is related to the arrhythmia
itself and to the prevention of thromboembolism.
Methods for nonpharmacological (surgical) corrections
to maintain sinus rhythms if drug failure occurs in-
cluding surgical ablation based on mapping studies of
animal and human AF, Cox developed a surgical pro-
cedure (maze operation) which involves encircling the
pulmonary veins by surgical incisions within the LA and
radial incisions in both atria that join the mitral and
tricuspid valve annuli.
Several catheter ablation strategies have been de-
signed to produce similar effects. The recognition that
foci triggering AF often originate within the pulmonary
veins, the superior vena cava, the RA and LA, and the
coronary sinus ablation of these foci eliminates or
reduces the frequency of AF. Although these procedures
have produced promising results, they have not yet
been widely applied. Suppression of AF by pacing as
a primary therapy for prevention of AF has not been
validated.
There has been an interest in internal atrial cardi-
overter/defibrillators of AF for the past 10 years.
Attempts have been made to find shock waveforms
that reduce the energy requirements for cardioversion,
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main objective of the HTA programme is the diffusion of
state of the art evidence without any mandatory role
regarding guidelines implementation or rationing in health
care. The HTA programme also provides support for the
work of the National Institute for Health and Clinical
Excellence (NICE), a governmental independent organisa-
tion with a more prominent role in priority setting. The
HTA programme is the interface between NICE and the
review groups contracted to produce the technology
assessment reports. All guidelines are published with the
expectation that they will be reviewed and updated when
new and relevant evidence is made available. Both the
HTA programme and NICE are tax-revenue funded, you can
find more about these organisations in their websites
(http://www.publichealth.nice.org.uk, http://www.hta.nhs
web.nhs.uk/).
Regarding Dr. Hudorovic´’s concern about the compara-
bility of the patients undergoing MRCP and ERCP, although
only the best of the available evidence was considered by
the review team, the quality of the studies was established
as moderate and it was difficult to ascertain whether
an appropriate spectrum of patients was included.
A systematic review was conducted by the systematic
reviewers team of the ScHARR Technology Assessment
Group (University of Sheffield, http://www.sheffield.
ac.uk/scharr/sections/heds/collaborations/scharr-tag), with
a total of 28 prospective diagnostic studies selected and as-
sessed using quality criteria. Only those studies where the
included patients had both diagnostic tests, and that
obtained MRCP efficacy against final diagnosis (on the
basis of surgical findings, percutaneous biopsy, clinical
follow-up and others) were used to inform the sensitivity
and specificity parameters in the model. More detail on
the studies is provided in the HTA monograph referenced
in the paper.
Dr. Hudorovic´ also seems to suggest that our results
could be questionable in the sense that ‘‘an improvement
of quality of life is dependent of the pre-procedural
base case values and independent of the pre-operative
co-morbidities’’. Following conventional practice, utility
values for the different health states were obtained
from the Harvard CUA database, using the states of per-
fect health and death as anchor values in order to esti-
mate the disutilities that would inform the model. The
impact of co-morbidities in quality of life was not consid-
ered as this was out of the scope of our project. The
publishing of the HTA monograph involves rigorous peer
review by experts in different fields (clinicians, statisti-
cians, modellers, health economists) so in case of a po-
tential methodological pitfall this would have been
noted and corrected before publication.
Finally, Dr. Hudorovic´ points that the decision to perform
MRCP or ERCP should take into account the operative risk.
Just to remind the reader that the risk of death derived
from a diagnostic ERCP and also the probability of overall
complications were explicitly incorporated in the probabi-
listic model, although, of course, patient choice is a
separate matter and should always be taken into consider-
ation before taking a decision.Yolanda Bravo Vergel
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